Pharmaceutical Executive January 20, 2025
The EY executive discusses trends in this sector and what he expects to see in the coming year.
The past few years have been a roller coaster ride for M&A in pharma and biotech. After the highs of the pandemic came crashing down, 2024 saw interest return to this sector in the industry. Subin Baral, global life sciences deals leader at EY, spoke with Pharmaceutical Executive about the past year in M&A and what 2025 potentially holds.
Pharmaceutical Executive: How significant an issue is pricing and access to drugs and medical devices?
Subin Baral: In general there is a steady trend towards need for more clinical and even real-world evidence to validate pricing levels and win reimbursement, and the provisions of...
Today's Sponsors
Today's Sponsor